Table 7.
Therapeutic Index values for the RRWQWR-based peptides against the clinical isolates of HCAI-relevant, Gram- positive bacteria.
| Peptide | Attribute | aHmax | MIC50 (μM) | bGm | cFold | Therapeutic index | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| (%) | (μM) | Enteroccocus faecium | Staphylococcus aureus | MHC/MIC50 | dFold | ||||||||||||
| 550 | 1040 | 1225 | 1461 | 1462 | 52013 | 43062 | 43337 | 48575 | 48577 | ||||||||
| PLS | Palindromic | 24.8 | 100.0 | 5.7 | 8.3 | 50.4 | 13 | 36.5 | 5.74 | 13.7 | 2.0 | 7.3 | 0.5 | ||||
| LfcinB (20–25)2 | Dimeric | 5.6 | 100.0 | 49.8 | 12.6 | 13.5 | 13.5 | 13.4 | 12.9 | 16.4 | 2.4 | 6.1 | 0.4 | ||||
| LfcinB (20–25)4 | Tetrameric | 49.1 | 100.0 | 6.7 | 6.7 | 6.3 | 9.2 | 6.3 | 7.0 | 1.0 | 14.4 | 1.0 | |||||
a
Hmax: Maximum Hemolytic Activity of the indicated peptide against human erythrocytes after 2 h of treatment at 37°C.
b
GM: geometric mean of the MIC50 values for the indicated peptide against the indicated bacterial strains.
c
Fold: Calculated as (GM for the indicated peptide)/(GM for the tetrameric peptide).
d
Fold: Calculated as (TI for the indicated peptide)/(TI for the tetrameric peptide).